Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Lumos Pharma Inc is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Lumos Pharma employs 32 staff and has a trailing 12-month revenue of around $734,000.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $9.05 |
|---|---|
| 52-week range | $6.15 - $10.58 |
| 50-day moving average | $8.49 |
| 200-day moving average | $8.33 |
| Wall St. target price | $23.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.05 from 2022-10-03
| 1 week (2022-09-27) | 0.56% |
|---|---|
| 1 month (2022-09-02) | 7.74% |
| 3 months (2022-07-01) | 17.69% |
| 6 months (2022-04-04) | 4.26% |
| 1 year (2021-10-04) | -1.95% |
|---|---|
| 2 years (2020-10-02) | -33.50% |
| 3 years (2019-10-04) | 647.93% |
| 5 years (2017-10-04) | 11.87 |
| Revenue TTM | $734,000 |
|---|---|
| Gross profit TTM | $230,000 |
| Return on assets TTM | -18.6% |
| Return on equity TTM | -32.67% |
| Profit margin | 0% |
| Book value | $8.90 |
| Market capitalisation | $74.8 million |
TTM: trailing 12 months
We're not expecting Lumos Pharma to pay a dividend over the next 12 months.
Lumos Pharma's shares were split on a 1:9 basis on 18 March 2020. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.
Over the last 12 months, Lumos Pharma's shares have ranged in value from as little as $6.15 up to $10.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lumos Pharma's is 0.8583. This would suggest that Lumos Pharma's shares are less volatile than average (for this exchange).
Lumos Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.